121 related articles for article (PubMed ID: 18945509)
1. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
Sadikot SM; Mogensen CE
Diabetes Res Clin Pract; 2008 Dec; 82(3):391-5. PubMed ID: 18945509
[TBL] [Abstract][Full Text] [Related]
2. Sulphonylureas and cancer: a case-control study.
Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
[TBL] [Abstract][Full Text] [Related]
3. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
[TBL] [Abstract][Full Text] [Related]
4. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
5. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
6. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Khalangot M; Tronko M; Kravchenko V; Kovtun V
Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
[TBL] [Abstract][Full Text] [Related]
7. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
8. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
[TBL] [Abstract][Full Text] [Related]
9. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
[TBL] [Abstract][Full Text] [Related]
10. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
Sillars B; Davis WA; Hirsch IB; Davis TM
Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
[TBL] [Abstract][Full Text] [Related]
11. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
Andersson C; Gislason GH; Jørgensen CH; Hansen PR; Vaag A; Sørensen R; Mérie C; Olesen JB; Weeke P; Schmiegelow M; Norgaard ML; Køber L; Torp-Pedersen C
Diabetes Res Clin Pract; 2011 Oct; 94(1):119-25. PubMed ID: 21831467
[TBL] [Abstract][Full Text] [Related]
12. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
[TBL] [Abstract][Full Text] [Related]
13. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.
Anselmino M; Ohrvik J; Malmberg K; Standl E; Rydén L;
Eur Heart J; 2008 Jan; 29(2):177-84. PubMed ID: 18156611
[TBL] [Abstract][Full Text] [Related]
14. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
Juurlink DN; Gomes T; Shah BR; Mamdani MM
Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
[TBL] [Abstract][Full Text] [Related]
15. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.
Tirkkonen T; Heikkilä P; Huupponen R; Laine K
J Intern Med; 2010 Oct; 268(4):359-66. PubMed ID: 20698928
[TBL] [Abstract][Full Text] [Related]
16. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
[TBL] [Abstract][Full Text] [Related]
17. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
[TBL] [Abstract][Full Text] [Related]
18. Medical therapy for diabetes is associated with increased use of lower endoscopy.
Lewis JD; Capra AM; Achacoso NS; Ferrara A; Levin TR; Quesenberry CP; Habel LA
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1195-202. PubMed ID: 17603822
[TBL] [Abstract][Full Text] [Related]
19. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
Holstein A; Hahn M; Stumvoll M; Kovacs P
Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
[TBL] [Abstract][Full Text] [Related]
20. Metformin and the sulphonylureas: the comparative risk.
Campbell IW
Horm Metab Res Suppl; 1985; 15():105-11. PubMed ID: 3935560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]